Distribution of platinum drug in tissue by combination of radiofrequency ablation and chemotherapy for experimental lung tumor

2018 Fiscal Year Final Research Report

• Project/Area Number: 17K16473
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Radiation science
• Research Institution: Osaka City University
• Principal Investigator: UEKI AI 大阪市立大学, 大学院医学研究科, 病院講師 (30551155)
• Research Collaborator: Okuma Tomohisa
• Project Period (FY): 2017-04-01 – 2019-03-31
• Keywords: RFA / プラチナ製剤 / 肺癌 / VX2

Outline of Final Research Achievements

The purpose of this study is to evaluate distribution of platinum preparations in tissue by combining Radiofrequency Ablation (RFA) and platinum doublet chemotherapy. The experiment was approved by the institutional animal care committee. VX2 cells were implanted into the lungs of rabbits randomized into groups treated with chemotherapy alone (CDDP/PTX), or a combination of RFA and chemotherapy (RFA/CDDP/PTX). RFA was performed and followed by intravenous chemotherapy. Platinum concentration in tissue of tumor, tissue of normal lung, and blood were measured a week after treatment and compared between chemotherapy alone group and combination group.
In the combination of chemotherapy and RFA group, there was no significant difference between the platinum concentration in the tumor and the platinum concentration in the peripheral area of the tumor. However, in this study, we demonstrated the efficacy of the combination of the chemotherapy and RFA.

Free Research Field

放射線診断/IVR学

Academic Significance and Societal Importance of the Research Achievements

最近の報告で早期肺癌に対するRFAの成績は手術成績より高いとする報告もあり、低侵襲治療であり短期間の入院で治療可能、さらに再治療ができる肺癌のRFAの治療成績を向上させる基礎研究には意義があると考えられる。当研究でRFA+抗癌剤併用が抗癌剤単独治療群と比較して、腫瘍での抗癌剤の組織内分布が有意に高いことが確認できれば、切除不能肺癌におけるRFA併用の考え方が大きく変わる可能性が期待され、臨床的にも非常に特色のある研究であると思われる。